CNBC
19 Jun 2026, 05:00 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Survodutide showed a patient dropout rate of 18.8% due to adverse events, significantly higher than the ~4% seen in leading therapies like Wegovy and Zepbound. — High discontinuation rates severely limit commercial viability and have led analysts to slash peak sales forecasts by nearly 80%.
-0.80Zealand Pharma's petrelintide is scheduled to initiate late-stage trials in the second half of the year and report mid-stage results for diabetes patients. — As the primary growth driver moving forward, these upcoming trials are the critical catalysts for stock recovery.
+0.50UBS analysts reduced their price target for Zealand Pharma from 730 to 540 Danish kroner following the survodutide data. — A significant price target cut by a major institution reflects a fundamental downward re-rating of the company's valuation.
-0.40Continue reading
6 related stories
Search tags
Petrelintide targets a 'sweet spot' of modest weight loss combined with high tolerability, potentially positioning it for weight maintenance after GLP-1 use. — Creates a distinct market niche that differentiates the drug from high-efficacy but high-side-effect competitors.
+0.30Multiple analysts, including Jefferies and UBS, indicate that a major inflection point for the company will likely not occur until 2027. — Suggests a long horizon for value realization, reducing the immediate appeal for short-term investors.
-0.20Which stocks this story touches
Described as a heavyweight with a dominant franchise and potentially the most efficacious obesity therapy in development.
Shares plunged due to high patient dropout rates and disappointing tolerability data for survodutide.
Noted as being strongly positioned in both current and future obesity markets.
Mentioned as a partner in the development of petrelintide.
[mutual] Both companies are developing amylin-based and other obesity medications.
[mutual] Zealand Pharma competes with Novo Nordisk in the obesity drug market.
[mutual] Zealand is developing petrelintide in partnership with Roche.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
14h ago
